Transcriptome-guided GLP-1 receptor therapy rescues metabolic and behavioral disruptions in a Bardet-Biedl syndrome mouse model
Journal of Clinical Investigation · 2025
DOI: 10.1172/jci184636 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Arashdeep Singh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Bardet-Biedl Syndrome, Transcriptome, Glucagon-Like Peptide-1 Receptor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIDDK, American Heart Association.
Abstract (Originalsprache)
Bardet-Biedl syndrome (BBS), a ciliopathy characterized by obesity, hyperphagia, and learning deficits, arises from mutations in Bbs genes. Exacerbated symptoms occur with mutations in genes encoding the BBSome, a complex regulating primary cilia function. We investigated the mechanisms underlying BBS-induced obesity using a Bbs5 -knockout ( Bbs5 –/– ) mouse model. Bbs5 –/– mice were characterized by hyperphagia, learning deficits, glucose/insulin intolerance, and disrupted metabolic hormones, phenocopying human BBS. White adipose tissue in these mice had a unique immunophenotype, with increased proinflammatory macrophages and dysfunctional Tregs, suggesting a mechanism for adiposity distinct from those of typical obesity models. Additionally, Bbs5 –/– mice exhibited pancreatic islet hyperplasia but failed to normalize blood glucose, suggesting defective insulin action. Hypothalamic transcriptomics revealed dysregulation of endocrine signaling pathways, with functional analyses confirming defects in insulin, leptin, and cholecystokinin (CCK) signaling, while glucagon-like peptide-1 receptor (GLP-1R) responsiveness was preserved. Notably, treatment with a GLP-1RA effectively alleviated hyperphagia and body weight gain, improved glucose tolerance, and regulated circulating metabolic hormones in Bbs5 –/– mice. This study suggests that Bbs5 –/– mice represent a valuable translational model of BBS for understanding pathogenesis and developing better treatments. Our findings highlight the therapeutic potential of GLP-1RAs for managing BBS-associated metabolic dysregulation, indicating that further investigation for clinical application is warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Monell Chemical Senses Center, Philadelphia, Pennsylvania, USA.
- Department of Neuroscience, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
- Department of Pharmacodynamics, College of Pharmacy, University of Florida, USA.
- Department of Genetics and Genomic Medicine, University College London, United Kingdom.
- Department of Medicine and.
- Department of Pathology, Immunology and Laboratory Medicine, College of Medicine, University of Florida, USA.
Förderung
- NIDDK NIH HHS
- NIDDK
- American Heart Association
Zitieren
APA
Singh, A., Haq, N., Yang, M., Luckey, S., Mansouri, S., Campbell-Thompson, M., Jin, L., Christou-Savina, S., & de Lartigue, G. (2025). Transcriptome-guided GLP-1 receptor therapy rescues metabolic and behavioral disruptions in a Bardet-Biedl syndrome mouse model. Journal of Clinical Investigation. https://doi.org/10.1172/jci184636
Vancouver
Singh A, Haq N, Yang M, Luckey S, Mansouri S, Campbell-Thompson M, et al. Transcriptome-guided GLP-1 receptor therapy rescues metabolic and behavioral disruptions in a Bardet-Biedl syndrome mouse model. Journal of Clinical Investigation. 2025. doi:10.1172/jci184636
BibTeX
@article{Singh2025,
author = {Singh, Arashdeep and Haq, Naila and Yang, Mingxin and Luckey, Shelby and Mansouri, Samira and Campbell-Thompson, Martha and Jin, Lei and Christou-Savina, Sofia and de Lartigue, Guillaume},
title = {Transcriptome-guided GLP-1 receptor therapy rescues metabolic and behavioral disruptions in a Bardet-Biedl syndrome mouse model},
journal = {Journal of Clinical Investigation},
year = {2025},
doi = {10.1172/jci184636}
}
EUVIMED